July 11, 2018
Mid-Year Review: New Drug Approvals Stay on   Track
By: Patricia Van Arnum, DCAT Editorial Director

As we reach the mid-point of 2018, how are approvals of new molecular entities faring? As of the end of June, the FDA had approved 20 NMEs, a similar number as approved this time last year when the FDA had approved 23 NMEs by mid-year with an eventual total of 46 NMEs approved for 2017. Although the numbers are on par, how about the drugs themselves?
Small molecules are dominating thus far, with 15 small-molecule NME approvals and five biologic-based NME approvals. Only one third (35%) of the approvals are from the pharmaceutical majors with small to mid-sized companies showing the NME muscle thus far.  DCAT Value Chain Insights  takes an inside look.
Strong Growth for the Oncology-Drug Market
By: Patricia Van Arnum, DCAT Editorial Director

What is the outlook for the cancer-drug market, the largest therapeutic area in the global pharmaceutical industry? Which new drugs are making the mark, and what are the key market trends?

The global oncology-drug market reached $133 billion in 2017. Spending on cancer drugs in the US has doubled since 2012 with the lion’s share of that growth tied to drugs launched within the past five years, according to a recent analysis by the IQVIA Institute for Human Data Science. In all, 14 new cancer therapeutics were launched in the US in 2017. This article is a highlighted feature from this year’s  DCAT Value Chain Insights .
VCI Headliners: Top Industry News
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of Pharmaceutical Technology from 2006 to 2014 and Executive Editor of ICIS Chemical Business and Chemical Market Reporter ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .